Is NAD+ FDA-approved?

What FDA approval actually covers

FDA approval applies to a specific product, made a specific way, for a specific use. The manufacturer submits evidence from clinical trials on safety and effectiveness, along with data on how the product is made and tested. FDA reviews it and, if satisfied, approves a label that says who the drug is for and how to use it.

No company has gone through that process for NAD+ injections. So there is no approved label, no FDA-reviewed dosing, and no FDA verification that any particular NAD+ product does what it claims. Lack of approval does not prove a product is unsafe or useless; it means those questions have not been answered to FDA's standard.

How compounded NAD+ fits in

Compounding is the preparation of a medication by a licensed pharmacy for an individual patient's prescription. It is legal and useful in many situations. But FDA states plainly that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed.

Most compounding for individual patients happens in state-licensed 503A pharmacies, which are overseen mainly by state boards of pharmacy. Larger 503B outsourcing facilities register with FDA and must follow current good manufacturing practice requirements. Both can be legitimate sources, but they are held to different standards.

NAD's place on FDA's bulk substance lists

A 503A pharmacy can only compound from a bulk ingredient if it meets certain conditions, such as being on FDA's approved list or falling under an interim policy for nominated substances. FDA sorts nominated substances into categories. Category 1 substances have enough supporting information to be evaluated and can be used while FDA decides. Category 2 substances raise significant safety concerns. Category 3 nominations lacked enough information.

On FDA's list updated in May 2026, nicotinamide adenine dinucleotide (NAD) is in Category 1. That allows pharmacies to compound it under the interim policy. It does not mean FDA has found it safe or effective, and the status could change when FDA completes its review.

Oral precursors live under supplement rules

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are sold as dietary supplements. Under supplement law, manufacturers are responsible for the safety and labeling of their products before sale, and FDA acts mainly after products reach the market. That is why quality and dose accuracy can vary by brand.

NMN had an unusual history. In 2022 FDA took the position that it could not be sold as a supplement because it had been studied as a drug. In letters dated September 29, 2025, FDA reversed that view and confirmed NMN is not excluded from the supplement definition, while companies still need to file new dietary ingredient notifications.

What 'not approved' should and should not change

It should change how you weigh claims. Without approval, there is no FDA-reviewed evidence that NAD+ improves energy, cognition or aging, and no regulator has checked that a given product contains what it says. Big promises deserve more skepticism, not less.

It should not, on its own, cause alarm. Many compounded medicines are used safely every day under a clinician's care. The practical response is to choose a licensed prescriber and a licensed pharmacy, start with realistic goals and keep an eye on how you respond.

Questions worth asking any NAD+ provider

A provider who answers these clearly, and who is honest that the evidence is early, is a better sign than one who promises reversed aging or guaranteed energy.

• Which pharmacy prepares the product, and is it a 503A pharmacy or a 503B outsourcing facility?
• Does the pharmacy test its products, and can it share how?
• What does the clinician check before prescribing, and how is follow-up handled?
• What specific goals are realistic, and when will we review whether it is helping?
• What side effects should I expect, and who do I contact if something feels wrong?

How HealifyMD handles it

At HealifyMD, a licensed clinician reviews your history before prescribing, and NAD+ is filled by a licensed U.S. compounding pharmacy. We describe it for what it is: a compounded product that is not FDA-approved, not equivalent to any branded drug and supported by early, mostly short-term evidence.

The NAD+ Injection starts from $199/month with no membership fee. Labs are priced separately, and your price is confirmed at the eligibility review.